デスモイド腫瘍の世界市場レポート 2025年

デスモイド腫瘍市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は6.8%で41億3,000万米ドルに成長します。予測期間の成長は、標的療法、個別化医療、国際共同研究の拡大、新規療法の規制承認、患者中心のアプローチに起因します。予測期間における主な動向としては、治療アプローチの進歩、精密医療とバイオマーカー探索、臨床試験と研究イニシアティブ、集学的治療チーム、患者擁護と支援などが挙げられます。

がんの罹患率の増加は、今後のデスモイド腫瘍市場の成長を促進すると予想されます。がんは、体内の異常細胞の制御不能な増殖と拡散を特徴とする疾患群を指し、近隣の組織や臓器に浸潤して重大な害をもたらす可能性があります。世界のがん患者の増加は、先進的で効果的な化学療法剤への需要を促進し、デスモイド腫瘍市場にプラスの影響を与えています。例えば、米国を拠点とする連邦政府機関である国立がん研究所によると、2024年5月に米国で新たにがんと診断される患者は推定2,001,140人で、この病気による死亡者数は611,720人と予測されています。2022年には、世界中で約2,000万人が新たにがんと診断され、970万人が死亡したと報告されています。2040年までには、年間新規がん患者数は2990万人に増加し、がん関連死は1530万人に達すると予測されています。その結果、がん患者の増加がデスモイド腫瘍市場の成長を促進しています。

研究開発のための政府資金配分の増加は、デスモイド腫瘍市場を後押しすると予想されます。政府からの資金援助は、科学的研究、医療インフラ、治療へのアクセス改善への財政支援を提供することで、腫瘍の研究と治療を進める上で極めて重要な役割を果たしています。これは最終的にがんの予防、診断、患者の転帰を向上させる。その一例として、米国議会が2023会計年度にCancer Moonshotのために国立がん研究所に割り当てた73億米ドルの予算は、2022年から4億800万米ドルの増加を示しています。その結果、研究開発のための政府資金の増加がデスモイド腫瘍市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界デスモイド腫瘍PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のデスモイド腫瘍市場：成長率分析
• 世界のデスモイド腫瘍市場の実績：規模と成長, 2019-2024
• 世界のデスモイド腫瘍市場の予測：規模と成長, 2024-2029, 2034F
• 世界デスモイド腫瘍総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のデスモイド腫瘍市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 放射線治療
• 抗炎症薬
• ホルモン療法
• 化学療法
• 新しい分子標的治療
• その他の治療法
• 世界のデスモイド腫瘍市場診断による、実績と予測, 2019-2024, 2024-2029F, 2034F
• 生検
• 電子顕微鏡検査
• 免疫組織化学分析
• その他の診断
• 世界のデスモイド腫瘍市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 専門センター
• その他のエンドユーザー
• 世界のデスモイド腫瘍市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 広範囲切除
• 低侵襲手術
• 世界のデスモイド腫瘍市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療
• 定位放射線治療
• 世界のデスモイド腫瘍市場抗炎症薬の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• コルチコステロイド
• 世界のデスモイド腫瘍市場ホルモン療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 選択的エストロゲン受容体モジュレーター（SERM）
• アロマターゼ阻害剤
• 世界のデスモイド腫瘍市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 従来の化学療法剤
• 併用化学療法
• 世界のデスモイド腫瘍市場、新規分子標的治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤
• その他の標的療法
• 世界のデスモイド腫瘍市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 用心深く待つ
• 理学療法
• 疼痛管理戦略

第7章 地域別・国別分析

• 世界のデスモイド腫瘍市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のデスモイド腫瘍市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• デスモイド腫瘍市場：競合情勢
• デスモイド腫瘍市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F.Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Abbott Laboratories
• Amgen Inc.
• Stryker Corporation
• Genome And Company
• Vertex Pharmaceuticals Incorporated
• Eisai Limited
• Beckman Coulter Inc.
• Incyte Corporation
• Ipsen Biopharmaceuticals Inc.
• BeiGene Ltd.
• Janssen Biotech Inc.
• Ionis Pharmaceuticals Inc.
• Ayala Pharmaceuticals Inc.
• Blueprint Medicines Corporation
• Xencor Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• デスモイド腫瘍市場2029：新たな機会を提供する国
• デスモイド腫瘍市場2029：新たな機会を提供するセグメント
• デスモイド腫瘍市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Desmoid tumors are rare non-cancerous (benign) growths originating from connective tissue cells, typically within the fascia- the tissue encompassing muscles, nerves, and blood vessels. Although locally aggressive, meaning they can grow and invade nearby structures, desmoid tumors differ from traditional cancers as they do not metastasize to distant parts of the body.

The primary treatments for desmoid tumors encompass surgical intervention, radiation therapy, anti-inflammatory medications, hormone therapy, chemotherapy, novel molecular-targeted therapy, and other therapeutic approaches. Surgery involves the removal or repair of tissues or organs within the body. The diagnosis of desmoid tumors employs various methods such as biopsy, electron microscopic examination, immunohistochemical analysis, and others. Medical professionals in hospitals, clinics, specialty centers, and similar healthcare facilities typically undertake these diagnostic and treatment procedures.

The desmoid tumors market research report is one of a series of new reports from The Business Research Company that provides desmoid tumors market statistics, including desmoid tumors industry global market size, regional shares, competitors with a desmoid tumors market share, detailed desmoid tumors market segments, market trends and opportunities, and any further data you may need to thrive in the desmoid tumors industry. This desmoid tumors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The desmoid tumors market size has grown strongly in recent years. It will grow from $2.97 billion in 2024 to $3.18 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to advancements in medical imaging, genetic research and understanding, surgical innovations, awareness and education, patient advocacy.

The desmoid tumors market size is expected to see strong growth in the next few years. It will grow to $4.13 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to targeted therapies, personalized medicine, expanded international collaborations, regulatory approvals for novel therapies, patient-centric approaches. Major trends in the forecast period include advancements in treatment approaches, precision medicine and biomarker discovery, clinical trials and research initiatives, multidisciplinary treatment teams, patient advocacy and support.

The increasing incidence of cancer is anticipated to drive the growth of the desmoid tumor market in the future. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body, which can invade nearby tissues and organs, causing significant harm. The global rise in cancer cases has spurred demand for advanced and effective chemotherapeutic agents, positively impacting the desmoid tumor market. For example, in May 2024, according to the National Cancer Institute, a U.S.-based federal government agency, an estimated 2,001,140 new cases of cancer are expected to be diagnosed in the U.S. in 2024, with 611,720 projected deaths from the disease. In 2022, nearly 20 million new cases and 9.7 million cancer-related deaths were reported worldwide. By 2040, the annual number of new cancer cases is expected to increase to 29.9 million, with cancer-related deaths projected to reach 15.3 million. Consequently, the rising cancer cases are driving the growth of the desmoid tumor market.

The increasing allocation of government funding for research and development is expected to boost the desmoid tumor market. Government funding plays a pivotal role in advancing tumor research and treatment by providing financial support for scientific studies, medical infrastructure, and improved access to care. This ultimately enhances cancer prevention, diagnosis, and patient outcomes. An example is the budget of $7.3 billion allocated to the National Cancer Institute by the United States Congress in fiscal year 2023 for the Cancer Moonshot, marking a $408 million increase from 2022. Consequently, the escalating government funding for research and development is fostering the growth of the desmoid tumor market.

Key companies in the desmoid tumors market are focusing on developing innovative drugs, such as nirogacestat, to address the needs of their existing consumers more effectively. Nirogacestat, an oral, small-molecule gamma-secretase inhibitor, has shown promise for treating desmoid tumors by blocking the production of notch proteins, contributing to tumor cell death. In February 2023, SpringWorks Therapeutics Inc. announced the acceptance and priority review of their new drug application (NDA) for nirogacestat by the U.S. Food and Drug Administration (FDA). This development provides patients with a new treatment option that holds the potential to improve outcomes.

In January 2023, the merger of Advaxis Inc. with Ayala Pharmaceuticals Inc., a US-based biotechnology company, aims to create a unified entity focused on developing and commercializing Ayala's lead program, AL102, for desmoid tumor treatment. The merger intends to expedite the development and commercialization of AL102, fostering a more diversified and robust cancer portfolio. Ayala Pharmaceuticals Inc. is actively developing AL102, a vaccine candidate designed to address the treatment of desmoid tumors.

Major companies operating in the desmoid tumors market report are Pfizer Inc., F.Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Abbott Laboratories, Amgen Inc., Stryker Corporation, Genome And Company, Vertex Pharmaceuticals Incorporated, Eisai Limited, Beckman Coulter Inc., Incyte Corporation, Ipsen Biopharmaceuticals Inc., BeiGene Ltd., Janssen Biotech Inc., Ionis Pharmaceuticals Inc., Ayala Pharmaceuticals Inc., Blueprint Medicines Corporation, Xencor Inc., MacroGenics Inc., Debiopharm Group, Clovis Oncology Inc., Juno Therapeutics Inc., SpringWorks Therapeutics Inc., Loxo Oncology Inc., Mirati Therapeutics Inc., Iterion Therapeutics Inc., Recepta Pharmaceuticals Inc., Cellestia Biotech AG

North America was the largest region in the desmoid tumors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the desmoid tumors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the desmoid tumors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The desmoid tumors market consists of revenues earned by entities by providing services such as gleevec-based therapy, sorafenib-based therapy, long-term monitoring, resonance imaging (MRI), computed tomography (CT) scans, ultrasound, and fine needle aspiration techniques (FNA) that aid in the diagnosis of desmoid tumors. The market value includes the value of related goods sold by the service provider or included within the service offering. The desmoid tumors market also includes sales of surgical tools, linear accelerators, immunotherapy drugs, and anti-fibrotic agents. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Desmoid Tumors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on desmoid tumors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for desmoid tumors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The desmoid tumors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Surgery; Radiation Therapy; Anti-Inflammatory Medication; Hormone Therapy; Chemotherapy; Novel Molecular-Targeted Therapy; Other Treatments
• 2) By Diagnosis: Biopsy; Electron Microscopic Examination; Immunohistochemical Analysis; Other Diagnosis
• 3) By End-User: Hospitals And Clinics; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Surgery: Wide Excision; Minimally Invasive Surgery
• 2) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy
• 3) By Anti-Inflammatory Medication: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs); Corticosteroids
• 4) By Hormone Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors
• 5) By Chemotherapy: Traditional Chemotherapy Agents; Combination Chemotherapy
• 6) By Novel Molecular-Targeted Therapy: Tyrosine Kinase Inhibitors; Other Targeted Therapies
• 7) By Other Treatments: Watchful Waiting; Physical Therapy; Pain Management Strategies
• Companies Mentioned: Pfizer Inc.; F.Hoffmann-La Roche Ltd.; Abbvie Inc.; Bayer AG; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Desmoid Tumors Market Characteristics

3. Desmoid Tumors Market Trends And Strategies

4. Desmoid Tumors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Desmoid Tumors Growth Analysis And Strategic Analysis Framework

• 5.1. Global Desmoid Tumors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Desmoid Tumors Market Growth Rate Analysis
• 5.4. Global Desmoid Tumors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Desmoid Tumors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Desmoid Tumors Total Addressable Market (TAM)

6. Desmoid Tumors Market Segmentation

• 6.1. Global Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Radiation Therapy
• Anti-Inflammatory Medication
• Hormone Therapy
• Chemotherapy
• Novel Molecular-Targeted Therapy
• Other Treatments
• 6.2. Global Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• Electron Microscopic Examination
• Immunohistochemical Analysis
• Other Diagnosis
• 6.3. Global Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Specialty Centers
• Other End-Users
• 6.4. Global Desmoid Tumors Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Wide Excision
• Minimally Invasive Surgery
• 6.5. Global Desmoid Tumors Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Stereotactic Body Radiation Therapy
• 6.6. Global Desmoid Tumors Market, Sub-Segmentation Of Anti-Inflammatory Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• 6.7. Global Desmoid Tumors Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Selective Estrogen Receptor Modulators (SERMs)
• Aromatase Inhibitors
• 6.8. Global Desmoid Tumors Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Traditional Chemotherapy Agents
• Combination Chemotherapy
• 6.9. Global Desmoid Tumors Market, Sub-Segmentation Of Novel Molecular-Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors
• Other Targeted Therapies
• 6.10. Global Desmoid Tumors Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Watchful Waiting
• Physical Therapy
• Pain Management Strategies

7. Desmoid Tumors Market Regional And Country Analysis

• 7.1. Global Desmoid Tumors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Desmoid Tumors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Desmoid Tumors Market

• 8.1. Asia-Pacific Desmoid Tumors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Desmoid Tumors Market

• 9.1. China Desmoid Tumors Market Overview
• 9.2. China Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Desmoid Tumors Market

• 10.1. India Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Desmoid Tumors Market

• 11.1. Japan Desmoid Tumors Market Overview
• 11.2. Japan Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Desmoid Tumors Market

• 12.1. Australia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Desmoid Tumors Market

• 13.1. Indonesia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Desmoid Tumors Market

• 14.1. South Korea Desmoid Tumors Market Overview
• 14.2. South Korea Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Desmoid Tumors Market

• 15.1. Western Europe Desmoid Tumors Market Overview
• 15.2. Western Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Desmoid Tumors Market

• 16.1. UK Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Desmoid Tumors Market

• 17.1. Germany Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Desmoid Tumors Market

• 18.1. France Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Desmoid Tumors Market

• 19.1. Italy Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Desmoid Tumors Market

• 20.1. Spain Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Desmoid Tumors Market

• 21.1. Eastern Europe Desmoid Tumors Market Overview
• 21.2. Eastern Europe Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Desmoid Tumors Market

• 22.1. Russia Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Desmoid Tumors Market

• 23.1. North America Desmoid Tumors Market Overview
• 23.2. North America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Desmoid Tumors Market

• 24.1. USA Desmoid Tumors Market Overview
• 24.2. USA Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Desmoid Tumors Market

• 25.1. Canada Desmoid Tumors Market Overview
• 25.2. Canada Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Desmoid Tumors Market

• 26.1. South America Desmoid Tumors Market Overview
• 26.2. South America Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Desmoid Tumors Market

• 27.1. Brazil Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Desmoid Tumors Market

• 28.1. Middle East Desmoid Tumors Market Overview
• 28.2. Middle East Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Desmoid Tumors Market

• 29.1. Africa Desmoid Tumors Market Overview
• 29.2. Africa Desmoid Tumors Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Desmoid Tumors Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Desmoid Tumors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Desmoid Tumors Market Competitive Landscape And Company Profiles

• 30.1. Desmoid Tumors Market Competitive Landscape
• 30.2. Desmoid Tumors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F.Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Desmoid Tumors Market Other Major And Innovative Companies

• 31.1. Abbott Laboratories
• 31.2. Amgen Inc.
• 31.3. Stryker Corporation
• 31.4. Genome And Company
• 31.5. Vertex Pharmaceuticals Incorporated
• 31.6. Eisai Limited
• 31.7. Beckman Coulter Inc.
• 31.8. Incyte Corporation
• 31.9. Ipsen Biopharmaceuticals Inc.
• 31.10. BeiGene Ltd.
• 31.11. Janssen Biotech Inc.
• 31.12. Ionis Pharmaceuticals Inc.
• 31.13. Ayala Pharmaceuticals Inc.
• 31.14. Blueprint Medicines Corporation
• 31.15. Xencor Inc.

32. Global Desmoid Tumors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Desmoid Tumors Market

34. Recent Developments In The Desmoid Tumors Market

35. Desmoid Tumors Market High Potential Countries, Segments and Strategies

• 35.1 Desmoid Tumors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Desmoid Tumors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Desmoid Tumors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer